PMID- 17378839
OWN - NLM
STAT- MEDLINE
DCOM- 20070517
LR  - 20191210
IS  - 1464-4096 (Print)
IS  - 1464-4096 (Linking)
VI  - 99
IP  - 4
DP  - 2007 Apr
TI  - Complexed prostate-specific antigen for the diagnosis of biochemical recurrence 
      after radical prostatectomy.
PG  - 758-61
AB  - OBJECTIVES: To determine the validity of using complexed prostate-specific 
      antigen (cPSA) levels for diagnosing biochemical recurrence after radical 
      prostatectomy (RP). PATIENTS AND METHODS: With linear regression modelling, we 
      determined threshold cPSA levels for biochemical recurrence in patients after RP 
      for clinically localized prostate cancer. We calculated sensitivity, specificity, 
      predictive values, and likelihood ratio tests of each threshold for diagnosing 
      biochemical recurrence using total PSA (tPSA) as the reference standard. RESULTS: 
      In the regression models, tPSA and cPSA were highly correlated (r = 0.99). For 
      the diagnosis of biochemical recurrence, tPSA thresholds of 0.20 and 0.40 ng/mL 
      corresponded to cPSA thresholds of 0.12 ng/mL (95% confidence interval 0.08-0.17) 
      and 0.29 (0.22-0.28) ng/mL, respectively. For the detection of biochemical 
      recurrence, a cPSA threshold of 0.12 ng/mL had a sensitivity of 96%, specificity 
      of 88%, positive predictive value of 89%, negative predictive value of 88%, 
      positive likelihood ratio of 8, and negative likelihood ratio of 0.05; the 
      respective values for a cPSA threshold of 0.29 ng/mL were 96%, 96%, 96%, 96%, 24 
      and 0.04. CONCLUSIONS: cPSA has high validity for the diagnosis of biochemical 
      recurrence after RP. Pending external validation, cPSA might be useful for 
      biochemical surveillance after RP.
FAU - Parsons, J Kellogg
AU  - Parsons JK
AD  - James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institution, 
      Baltimore, MD, USA. jkparsons@ucsd.edu
FAU - Partin, Alan W
AU  - Partin AW
FAU - Trock, Bruce
AU  - Trock B
FAU - Bruzek, Debra J
AU  - Bruzek DJ
FAU - Cheli, Carol
AU  - Cheli C
FAU - Sokoll, Lori J
AU  - Sokoll LJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Cohort Studies
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/*diagnosis
MH  - Predictive Value of Tests
MH  - Prostate-Specific Antigen/*metabolism
MH  - Prostatectomy/*methods
MH  - Prostatic Neoplasms/*diagnosis/surgery
MH  - Regression Analysis
MH  - Sensitivity and Specificity
EDAT- 2007/03/24 09:00
MHDA- 2007/05/18 09:00
CRDT- 2007/03/24 09:00
PHST- 2007/03/24 09:00 [pubmed]
PHST- 2007/05/18 09:00 [medline]
PHST- 2007/03/24 09:00 [entrez]
AID - BJU6680 [pii]
AID - 10.1111/j.1464-410X.2007.06680.x [doi]
PST - ppublish
SO  - BJU Int. 2007 Apr;99(4):758-61. doi: 10.1111/j.1464-410X.2007.06680.x.